NCT04126707View on ClinicalTrials.gov

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 19, 2019

Primary Completion Date

January 13, 2020

Study Completion Date

January 13, 2020

Conditions
Chronic Myeloid Leukemia (CML)
Interventions
DRUG

[14C] HQP1351

Orally, single dose of 30mg

Trial Locations (1)

Unknown

The First Affiliated Hospital with Nanjing Medical University, Nanjing

Sponsors
All Listed Sponsors
collaborator

HealthQuest Pharma Inc.

INDUSTRY

lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT04126707 - The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans | Biotech Hunter | Biotech Hunter